lumiracoxib selective inhibitor nonsteroidal antiinflammatory drug structure different inhibitors celecoxib lumiracoxib analogue diclofenac one chlorine substituted fluorine phenylacetic acid another methyl group meta position making member arylalkanoic acid class nsaids binds different site enzyme inhibitors acidic coxib highest selectivity patented approved medical use manufactured novartis still sold countries including mexico ecuador dominican republic trade name lumiracoxib withdrawn market several countries mostly due potential causing liver failure sometimes requiring liver transplantation never approved use united target study therapeutic arthritis research gastrointestinal event trial conducted patients test gastrointestinal cardiovascular safety naproxen ibuprofen also study efficacy two nsaids november prexige received marketing approval european union countries common procedure called mrp however august prexige withdrawn market australia following serious liver adverse events including deaths liver september us food drug administration issued approvable letter lumiracoxib requiring additional safety canada withdrew prexige approved mg dose october several european union countries followed suit november fda rejected prexige trade name lumiracoxib prexede suggested alternative fda division medication errors technical support dmets subsequently recommended august australias therapeutic goods administration tga national agency responsible regulation pharmaceuticals cancelled registration lumiracoxib australia due concerns may cause liver according tgas principal medical adviser dr rohan hammett august tga received reports serious adverse liver reactions drug including two deaths two liver transplants tga expert advisory committee adverse drug reactions advisory committee adrac urgently investigated reports adrac today recommended cancellation registration lumiracoxib due severity reported side effects associated drug dr hammett said tga taken advice cancel registration lumiracoxib order prevent cases severe liver damage seems longer people medicine greater chance liver injury tga therefore advising people stop taking lumiracoxib immediately discuss alternative treatments doctor dr hammett new zealand followed suit australia recalling october health canada requested sales prexige stop novartis agreed request taken steps december european medicines agency recommended withdrawal prexige eu january philippines department health ordered novartis healthcare phils inc novartis remove recall lumiracoxib local drug stores weeks due harmful effects drug potential serious liverrelated side effects hepatotoxicity malfunction july brazilian national health surveillance agency ordered withdrawal mg formulations lumiracoxib suspended marketing mg formulation threeyear safety review found marked increase adverse event reports lumiracoxibassociated adverse events reported worldwide july april found occurred lumiracoxib definitively withdrawn brazilian market october november invima colombian national institute food drug surveillance ordered withdrawal presentations lumiracoxib prexige due international reports hepatotoxicity httpsenwikipediaorgwikilumiracoxib